Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Quest Diagnostics (DGX) reported earnings 30 days ago. What's next for the stock?
Quest Diagnostics Incorporated (DGX) Presents at Leerink Global Healthcare Conference 2026 Transcript
Quest Diagnostics posts strong gains from physician and hospital channels while advancing AI-powered solutions.
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Quest Diagnostics (DGX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
DGX tops Q4 EPS and revenue estimates as volumes rise, shares jump premarket, and 2026 guidance points to steady growth.
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Quest Diagnostics (DGX) came out with quarterly earnings of $2.42 per share, beating the Zacks Consensus Estimate of $2.35 per share. This compares to earnings of $2.23 per share a year ago.
DGX heads into Q4 earnings with expected revenue and EPS growth, DIS momentum, and benefits from Fresenius assets and consumer testing.
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.